Pharmaceuticals

Radioligand Therapy Market Insights Report: Opportunities and Drivers 2030

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the radioligand therapy market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Radioligand Therapy Market covering 2026–2035?

The radioligand therapy market size has seen significant growth in recent years. This market is expected to expand from $6.63 billion in 2025 to $7.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. The expansion observed in the past can be ascribed to several factors, including the constrained supply of radioligands, the previous dependence on standard cancer therapies, heightened understanding of the advantages of targeted therapy, increasing integration of nuclear medicine techniques by hospitals, and the granting of regulatory approvals for initial radioligand therapy drugs.

The radioligand therapy market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $10.72 billion, exhibiting a compound annual growth rate (CAGR) of 10.0%. This anticipated growth during the forecast period is driven by several factors, including the emergence of new alpha and beta emitters, the broadening scope of combined emission therapies, their integration with precision oncology, an increase in clinical trials targeting neurological and cardiovascular conditions, and greater investment in home care and outpatient rlt services. Key trends expected over the forecast period encompass the growing acceptance of targeted radioligand therapy in oncology, the proliferation of alpha and beta emitter-based treatments, the incorporation of radioligand therapy into personalized medicine strategies, an increase in rlt programs within hospitals and research institutions, and an intensified focus on reducing adverse effects while improving patient results.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Radioligand Therapy Market?

The rising incidence of cancer is anticipated to stimulate the expansion of the radioligand therapy market in the future. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells, which can infiltrate surrounding tissues and spread throughout the body. The escalation in cancer cases stems from prolonged exposure to environmental pollutants that damage DNA, disrupt cellular function, and encourage irregular cell growth. Radioligand therapy addresses cancer by precisely directing radiation to tumor cells through ligands that bind to specific receptors, thereby minimizing harm to healthy tissues and eradicating cancer cells internally. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, averaging 972 per day, which signifies 8,605 more than in 2022. Consequently, the increasing cancer incidence is a key factor propelling the growth of the radioligand therapy market.

What Leading Segments Are Studied In The Radioligand Therapy Market?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

Which Trends Are Guiding The Evolution Of The Radioligand Therapy Market?

Leading companies in the radioligand therapy market are concentrating on developing sophisticated solutions, specifically radioligand therapy facilities, to boost production efficiency and uphold consistent quality and safety standards throughout the manufacturing and distribution processes of targeted cancer treatments. Radioligand therapy facilities are specialized centers crafted for managing and delivering radioactive drugs for precise cancer treatment, employing advanced imaging systems and radiation shielding, all while guaranteeing safety through well-trained personnel and stringent protocols. For example, in January 2024, Novartis AG, a pharmaceutical company based in Switzerland, announced the automation of its new substantial radioligand therapy (RLT) production plant located in Indiana. This facility obtained Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility stands as Novartis’s largest and most advanced site dedicated to RLT, engineered for efficient, time-sensitive production, and encompasses plans for entirely automated production lines, which will facilitate considerable supply increases to meet the rising patient demand across the US and Canada.

Which Major Firms Are Strengthening Their Position In The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Radioligand Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company

Property Management Service Market Report 2026

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795